Guillain-Barre Syndrome Pipeline

DelveInsight’s, “Guillain-Barre Syndrome - Pipeline Insight, 2025” report provides comprehensive insights about 2+ companies and 3+ pipeline drugs in Guillain-Barre Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Guillain-Barre Syndrome: Understanding

Guillain-Barre Syndrome: Overview

Guillain-Barré syndrome (GBS), the leading cause of acute flaccid neuromuscular paralysis in the United States, was first identified over a century ago. Since then, significant progress has been made in understanding its immune-mediated pathophysiology, characterizing its diverse clinical presentations, refining diagnostic and prognostic tools, and conducting randomized clinical trials that have improved treatment outcomes.

Guillain-Barré syndrome (GBS) and its variants are post-infectious, immune-mediated neuropathies primarily driven by molecular mimicry. Infections such as Campylobacter jejuni can trigger an immune response against bacterial lipooligosaccharides that resemble nerve gangliosides, leading to cross-reactive nerve damage. Up to 70% of patients report a preceding gastrointestinal or respiratory illness within 1–6 weeks of onset, with other associations including the Zika virus, certain medications, and surgeries. Vaccination has also been linked, most notably the 1976 influenza A/H1N1 vaccine, though later studies show the risk of GBS is far greater following flu infection than vaccination.

Guillain-Barré syndrome (GBS) often follows antecedent infections, with molecular mimicry playing a central role, especially in axonal variants. Campylobacter jejuni lipooligosaccharides resemble peripheral nerve gangliosides, triggering cross-reactive antibodies that damage nerves and activate the complement cascade. Different ganglioside antibodies target distinct nerve sites, contributing to varied clinical presentations, for instance, anti-GQ1B with Miller-Fisher syndrome, anti-GM1 with axonal motor neuropathy, and anti-GT1A with the pharyngeal-cervical-brachial variant. However, antibody sensitivity and specificity remain limited, and not all patients test positive, highlighting the need for further research. While the acute inflammatory demyelinating polyneuropathy (AIDP) variant is the most common in the U.S., its pathophysiology is less well understood.

Key diagnostic clues include atypical features such as early bowel or bladder involvement, asymmetry, or preserved/hyperactive reflexes, which suggest alternative causes. Ancillary tests support diagnosis, electromyography and nerve conduction studies help differentiate GBS from other neuropathies, while cerebrospinal fluid analysis showing albuminocytologic dissociation supports GBS, whereas pleocytosis indicates possible infectious etiologies.

The standard treatments for Guillain-Barré syndrome (GBS) are intravenous immunoglobulin (IVIG) and plasma exchange, both of which are equally effective when initiated within four weeks, ideally within two weeks, of symptom onset. IVIG works through immune modulation, though its precise mechanism is unclear, and is administered at 2 g/kg over five days. Plasma exchange removes pathogenic antibodies, humoral mediators, and complement proteins through five exchange sessions, though its mechanism is also not fully defined. Corticosteroids, either alone or combined with these therapies, have not shown benefit. Overall, treatment primarily accelerates recovery, with studies showing that treated patients regain independent ambulation significantly earlier than those untreated.

 

"Guillain-Barre Syndrome- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Guillain-Barre Syndrome pipeline landscape is provided which includes the disease overview and Guillain-Barre Syndrome treatment guidelines. The assessment part of the report embraces, in depth Guillain-Barre Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Guillain-Barre Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Guillain-Barre Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Guillain-Barre Syndrome.

 

Guillain-Barre Syndrome Emerging Drugs Chapters

This segment of the Guillain-Barre Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Guillain-Barre Syndrome Emerging Drugs

• ANX005: Annexon Biosciences

ANX005 is a clinical-stage monoclonal antibody developed by Annexon to treat Guillain-Barré Syndrome (GBS), a condition caused by autoantibody-mediated damage to peripheral nerves through activation of the complement cascade. Administered intravenously, ANX005 works by inhibiting C1q and blocking the classical complement pathway to prevent neurodegeneration and cognitive decline. The therapy has been granted Fast Track and Orphan Drug designations by the U.S. FDA and Orphan Drug status by the European Medicines Agency for the treatment of GBS. Currently, the drug is in Phase III stage of its clinical study for the treatment of Guillain-Barre Syndrome.

 Further product details are provided in the report……..

 

Guillain-Barre Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Guillain-Barre Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

 

Major  Players in Guillain-Barre Syndrome

• There are approx. 2+ key companies which are developing the therapies for Guillain-Barre Syndrome. The companies which have their Guillain-Barre Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Annexon Biosciences.

 

Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Guillain-Barre Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Guillain-Barre Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Guillain-Barre Syndrome therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Guillain-Barre Syndrome drugs.

 

Guillain-Barre Syndrome Report Insights

• Guillain-Barre Syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Guillain-Barre Syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Guillain-Barre Syndrome drugs?
• How many Guillain-Barre Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Guillain-Barre Syndrome?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Guillain-Barre Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Guillain-Barre Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?